Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04762160
Title A Trial to Examine Combination of Tazemetostat and Rituximab for Patients With Recurrent/Refractory Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Epizyme, Inc.

follicular lymphoma


Rituximab + Tazemetostat

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.